A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07113522, who can take part
Where in Canada
- TorontoToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mirador Therapeutics, Inc.
- Trial code
- NCT07113522
- Record updated
- 12 March 2026
- Original description
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.Read full original descriptionShow less
A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics With Multiple Therapies in Participants With Active Crohn's Disease or Active Ulcerative Colitis (ASCEND-IBD)
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
Inclusion: Diagnosis of Crohn's Disease (CD), as confirmed by endoscopy and histopathology; Moderately to severely active CD as defined by Clinical Disease Activity Index (CDAI) and Simple Endoscopic Score (SES-CD); Meets drug stabilization requirements; Diagnosis of Ulcerative Colitis (UC), as confirmed by endoscopy and histopathology; Moderately to severely active UC as defined by a 3-component MMCS; Meets drug stabilization requirements.
Exclusion: Previous small bowel resection with combined resected length of > 100 cm or previous colonic resection of > 2 segments; Received IV corticosteroids within 14 days prior to Screening or during the Screening Phase; Previous total proctocolectomy or subtotal colectomy; Current evidence or within recent history (within last 6 months) of fulminant colitis, toxic megacolon, or bowel perforation; Diagnosis of indeterminate colitis; Suspected or diagnosed intra-abdominal or perianal abscess at Screening; CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or ileal involvement; Current stoma or impending need for colostomy or ileostomy.